FDA Extends Comment Period for Draft Guidance on Unapproved Medical Product Uses

Summary

The Food and Drug Administration (FDA) is extending the comment period for its revised draft guidance on communications between pharmaceutical companies and healthcare providers regarding unapproved uses of approved medical products, following requests from interested parties for an additional time frame to submit comments.